AccessibilityHelpAbout Us
Cspc Pharmaceutical Group logo

Cspc Pharmaceutical Group(OTC) CSPCY

Market Cap$13.48BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)+88%
5 Year+16%
1 Year+2%
1 Month+2%
$4.76
+1.28%
+0.06Today
Cspc Pharmaceutical Group last closing stock price
MetricPriceDate
Last closeUSD 4.702026-09-24
Cspc Pharmaceutical Group stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+4.68%USD 4.492026-09-17
1 month+2.4%USD 4.592026-08-25
3 month+43.29%USD 3.282026-06-26
Year to date+11.49%USD 4.222025-12-31
1 year+2.2%USD 4.602025-09-24
3 year+80.67%USD 2.602023-09-25
5 year+16.44%USD 4.042021-09-24
Since inception+87.89%USD 2.502018-12-28

Cspc Pharmaceutical Group Financials at a Glance

Market Cap

$13.48BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥46.26B

Net Income (TTM)

CN¥8.99B

EPS (TTM)

$0.38

P/E Ratio

12.47

Dividend

$0.15

Beta (Volatility)

0.46 (Low)

Price

$4.76

Volume

102

Open

$4.76

Previous Close

$4.70

Daily Range

$4.76 - $4.76

52-Week Range

$3.26 - $5.46

Estimated Earnings Date

Aug 14, 2024

CSPCY News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cspc Pharmaceutical Group

CSPC Pharmaceutical Group Limited is a leading pharmaceutical company based in China, specializing in the manufacture and sale of a diverse range of pharmaceutical products. The company operates across various segments, including Finished Drugs, Bulk Products, and Functional Food, catering to both domestic and international markets.

Products and Services
  • Offers a wide range of medications for various health conditions
  • Provides functional food products and healthcare services
  • Engages in strategic collaborations for drug development
Growth Outlook
  • Revenue of CNY 18.39 billion in Q2 2026, showing strong demand
  • Net income margin of 32.77% indicates effective cost management
  • Strategic partnerships, including with AstraZeneca, enhance innovation potential
Financial Highlights
  • Trailing twelve months (TTM) revenue of CNY 56.04 billion reflects robust growth
  • Operating income margin of 39.51% demonstrates operational efficiency
  • Dividend yield of 3.10% offers attractive returns to shareholders
CSPC Pharmaceutical Group Limited has established itself as a significant player in the pharmaceutical industry, with a strong focus on research and development. The company's diverse product portfolio addresses various health issues, from cancer treatments to functional foods. Recent financial performance highlights a solid revenue growth trajectory, supported by a high net income margin, which underscores effective management practices. The strategic collaboration with AstraZeneca further positions CSPC for future growth, enhancing its capabilities in drug discovery and development. With a competitive dividend yield, CSPC presents an appealing opportunity for investors looking to engage with a dynamic and innovative pharmaceutical company.
AI Generated • Sep 25, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

19,700

CEO

Lei Cai, PhD

Website

www.cspc.com.hk

Headquarters

Shijiazhuang, HE 050035, CN

CSPCY Financials

Key Financial Metrics (TTM)

Gross Margin

71.86%

Operating Margin

27.95%

Net Income Margin

23.73%

Return on Equity

20.68%

Return on Capital

11.41%

Return on Assets

13.07%

Earnings Yield

8.02%

Dividend Yield

3.16%

Payout Ratio

33.54%

Stock Overview

Market Cap

$13.48BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.87B

Volume

102

Avg. Volume

1.40K

Financials (TTM)

Gross Profit

CN¥40.26B

Operating Income

CN¥12.79B

EBITDA

CN¥15.53B

Operating Cash Flow

CN¥17.49B

Capital Expenditure

-CN¥3.24B

Free Cash Flow

CN¥14.25B

Cash & ST Invst.

CN¥18.49B

Total Debt

CN¥652.72M

Cspc Pharmaceutical Group Performance Analysis

Cspc Pharmaceutical Group annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 4,594,329,9966.3%
20232023-12-31CNY 4,438,953,006-3.4%
20242024-12-31CNY 4,030,844,707-9.2%
20252025-12-31CNY 3,617,745,264-10.2%
Cspc Pharmaceutical Group sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-15.8%
Q22025-06-30-87.8%
Q42025-12-31647.8%
Q22026-06-3047.2%
Cspc Pharmaceutical Group annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY 0.304.4%
20232023-12-31CNY 0.28-8.0%
20242024-12-31CNY 0.20-26.6%
20252025-12-31CNY 0.19-7.7%
Cspc Pharmaceutical Group sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-59.3%
Q22025-06-30-74.5%
Q42025-12-31328.6%
Q22026-06-30341.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥18.39B

+13.0%

Gross Profit

CN¥14.00B

+20.2%

Gross Margin

76.15%

N/A

Market Cap

$13.48BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$684.50K

N/A

Employees

19,700

N/A

Net Income

CN¥6.03B

+99.6%

EBITDA

CN¥7.92B

+75.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥18.49B

+71.1%

Total Debt

CN¥652.72M

+67.9%

Accounts Receivable

CN¥8.48B

-28.8%

Inventory

CN¥2.96B

-14.3%

Long Term Debt

CN¥389.13M

+486.8%

Short Term Debt

CN¥263.59M

-18.3%

Return on Assets

13.07%

N/A

Return on Invested Capital

20.73%

N/A

Free Cash Flow

CN¥10.23B

+1219.0%

Operating Cash Flow

CN¥11.04B

+674.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RCDTFRecordati S.p.A.
$58.00+0.00%
ERFSFEurofins Scientific SE
$90.61+0.68%
BDULFBangkok Dusit Medical Services Public Company Limited
$0.69+23.21%
BIOVFSwedish Orphan Biovitrum AB (publ)
$48.13+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
GLNDGreenland Energy
$5.61+4.77%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.95-2.98%
INTCIntel
$124.51-2.26%
AALAmerican Airlines Group
$13.81+3.45%

Questions About CSPCY

What is the current price of Cspc Pharmaceutical Group?

Cspc Pharmaceutical Group is trading at $4.76 per share.

What is the 52-week range for Cspc Pharmaceutical Group?

Over the past 52 weeks, Cspc Pharmaceutical Group has traded between $3.26 and $5.46.

How much debt does Cspc Pharmaceutical Group have?

As of the most recent reporting period, Cspc Pharmaceutical Group reported total debt of CN¥91.74M.

How much cash does Cspc Pharmaceutical Group have on hand?

Cspc Pharmaceutical Group reported CN¥754.52M in cash and cash equivalents in its most recent financial results.

What is Cspc Pharmaceutical Group’s dividend yield?

Cspc Pharmaceutical Group currently has a dividend yield of 3.16%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services